Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
1.860
-0.040 (-2.11%)
Aug 17, 2026, 4:00 PM EDT - Market closed
Tvardi Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Tvardi Therapeutics stock has a consensus rating of "Buy" and an average price target of $8.50. The average 1-year stock price forecast is 356.99% higher than the current stock price, while the lowest is $3.00 (+61.29%) and the highest is $13 (+598.92%).
Price Target: $8.50 (+356.99%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Tvardi Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 2 | 2 |
| Hold | 4 | 3 | 3 | 3 | 1 | 1 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Sell Maintains $3 | Sell | Maintains | $3 | +61.29% | Aug 17, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $9 | Buy | Maintains | $9 | +383.87% | Aug 14, 2026 |
| BTIG | BTIG | Buy Maintains $15 → $5 | Buy | Maintains | $15 → $5 | +168.82% | Aug 14, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $12 | Buy | Maintains | $12 | +545.16% | Aug 11, 2026 |
| Piper Sandler | Piper Sandler | Buy Upgrades $13 | Buy | Upgrades | $13 | +598.92% | Jul 8, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.57
from -2.46
EPS Next Year
-2.15
from -2.57
EPS and Forward PE are based on non-GAAP adjusted numbers.